FDA to review fosdenopterin for molybdenum cofactor deficiency (MoCD) Type A

This cyclic pyranopterin monophosphate substrate replacement therapy has Orphan Drug Designation in EU.. Currently, there are no approved therapies for MoCD Type A, which results in severe and irreversible neurological injury with a median survival between 3 to 4 years.

Source:

Biospace Inc.